Phone: 614/488-2118
Fax: 614/488-2647
1335 Dublin Rd., Suite 124A
Columbus, OH 43215
Member Sign in
HOME
MEMBERS
CANCER RESOURCES
ABOUT
EVENTS
EMPLOYMENT
CONTACT
Protocol Database
User Profile
Index of Forms
Ohio Partners for Cancer Control
Consortium Members
Treatment Sites & Physicians
Community Based Research Nurses
NCORP Videos
Our Team
Donate
HOME
MEMBERS
Protocol Database
User Profile
Index of Forms
CANCER RESOURCES
Ohio Partners for Cancer Control
ABOUT
Consortium Members
Treatment Sites & Physicians
Community Based Research Nurses
NCORP Videos
EVENTS
EMPLOYMENT
CONTACT
Our Team
Donate
Enter your search term
Protocol Categories
View All Protocols
Brain
Breast
CA Control
CCDR
Gastrointestinal
Genitourinary
GYN
Head and Neck
Hematology
Lung
Lymphoma
Melanoma / Skin-Other
Multiple Disease Sites
Observational
RT
Sarcoma
Unknown Primary
DCP
Genitourinary
Alliance A031702
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Alliance A031704
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
COG AGCT1531
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
ECOG EA8183
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
NRG GU005
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
SWOG S1806
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
SWOG S1823
A Prospective Observational Cohort Study to Assess miRNA 371 For Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
Wake Forest WF 1802
Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)